Life Science News
Latest updates from the biotech and pharma world
Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3
#mRNA flu#Pfizer mRNA#flu vaccine#greater efficacy#greater effectiveness
CDC updates website to say vaccines may cause autism without new evidence
#CDC updates#updates website#webpage undercut#medical community#community consensus
The Cooper Companies under activist pressure to split—in different ways
#Cooper Companies#past month#activist pressure#Activist investors#outlined dueling
Moderna's reshaping rolls on with 3 more pipeline purges
#Moderna reshaping#vaccine Spikevax#pipeline purges#infectious diseases#mRNA programs
How a 'healthy exchange of ideas' with RFK Jr. kick-started FDA's gene therapy push
#Tim Hunt#Human Services#early March#kick-started FDA#FDA gene
GE HealthCare to acquire imaging software provider Intelerad for $2.3B
#cardiology practices#clinical trials#provider Intelerad#imaging business#software provider
Fierce Biotech Layoff Tracker 2025: Applied Tx lays off 46% of staff; Ensoma makes cuts
#Fierce Biotech#Layoff Tracker#Ensoma makes#makes cuts#editorial team
In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation
#Marty Makary#Director Marty#FDA Director#FDA stability#biotech CEOs
Contineum's J&J-partnered MS drug fails to improve vision in phase 2
#Contineum Therapeutics’#receptor antagonist#multiple sclerosis#drug fails#common form
FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process
#review process#pilot communication#comms program#communication program#FDA
GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement
#GSK Tesaro#Jemperli agreement#GSK subsidiary#subsidiary Tesaro#life span
Nurix trims workforce as pivotal trial for lead BTK degrader kicks off
#Nurix Therapeutics#Nurix trims#BTK degrader#cancer asset#lead BTK
Roche inks $200M-plus licensing pact for Freenome's cancer screening blood tests
#Roche inks#licensing pact#million equity#Freenome cancer#blood tests
Chutes & Ladders—Gilead abruptly parts ways with general counsel
#Deborah Telman#filing Nov.#Gilead abruptly#general counsel#affairs Deborah
CDC instructs researchers to end all monkey studies by year-end: Science
#Science reported#CDC instructs#instructs researchers#instructing scientists#research involving
Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission
#Dayra Therapeutics#Versant Ventures#oral macrocyclic#macrocyclic peptide#Versant Dayra
J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2
#Alzheimer hope#anti-tau antibody#antibody posdinemab#hope fades#disease drug
Abbott to replace certain FreeStyle Libre 3 CGMs after incorrect readings and death reports
#FreeStyle Libre#million FreeStyle#death reports#Libre#incorrect readings
Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program
#Sprint Bioscience#cancer program#Swedish biotech#Gilead hatches#million upfront